Briefcase

Treatment Factors: What Should Be Driving My Treatment Decisions?

Launch Date
08/04/2023 at 4:00 am EST
Credit Amount
0.5
Credit Expires
08/04/2024
This activity is part of a series

Faculty

Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School
Columbia, SC
Medical University of South Carolina
Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.

Explore By Section
Statement of Need Learning Objective Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Obstructive sleep apnea (OSA) with associated excessive daytime sleepiness (EDS) negatively and diversly impacts millions of patients. With the goal of improving patient quality of life, health care professionals (HCPs) will explore the constellation of symptoms patients with OSA-associated EDS may experience and will consider real-world treatment strategies to personalize care and optimize outcomes—like in our patient, Donovan, who initiated continuous positive airway pressure (CPAP) treatment 3 months ago but continues to be “tired all the time” and experiences negative work consequences and personal safety concerns.

Join us for this second of three BriefCase activities in which our expert faculty interweaves foundational knowledge with exercises for HCPs to practice new learnings with a case that emulates a patient with OSA and EDS seen in clinical practice.

Learning Objective

Evaluate the constellation of patient symptoms (e.g., EDS, cognitive impairment, functioning) that influence treatment selection for EDS associated with OSA.

Financial Support

Supported by an educational grant from Axsome.

Target Audience

Sleep specialists, neurologists, psychiatrists, pulmonologists, primary care practitioners, nurse practitioners (NPs), physician associates (PAs), and pharmacists

Credit Information

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Bogan reports the following financial relationships:

Consultant: Avadel; Axsome Therapeutics, Inc.; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; Oventus; and Takeda Pharmaceuticals U.S.A., Inc.

Research Support: Apnimed; Avadel; Bayer; Bresotec Medical; Eisai Inc.; Fisher Paykel Healthcare; FRESCA Medical; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; NLS Pharmaceutics; Philips; Roche; Sanofi; Sommetrics, Inc.; Suven Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc.

Speakers Bureau: Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals US Inc.; and Jazz Pharmaceuticals, Inc.

Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report::

  • Joshua Caballero, PharmD, BCPP, FCCP (peer reviewer)
  • Evan Luberger (planning committee)
  • Meghann Taft-Lockard (planning committee)
  • John Jones, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

BC-098-080423-84

Treatment Factors: What Should Be Driving My Treatment Decisions?
Event Date: 08/04/2023 at 4:00 am EST
Register

Activities in the Series